moratorium now!

On Friday 24 September 2021, I sent the below email to politicians and education bodies in Northern Ireland. I also included an attached copy of my risk assessment.

Dear ■■■■■,

I am writing today to inform you of the unacceptable risks in deploying the experimental COVID-19 genetic vaccines.

My fully independent, fully referenced biosecurity risk assessment thoroughly expounds upon all the risks documented across the fields of toxicology, molecular biology, virology, immunology and molecular, genomic and statistical epidemiology. It is hosted at alltherisks.com. I've also attached it to this email.

It highlights the exact pathologies associated with these genetic vaccines, explaining precisely how these experimental vaccines damage the body in devastating ways.

It also proves that, even prior to COVID-19, the strategy of mass vaccinating the population with non-sterilising vaccines targeting a highly mutable surface protein (spike) during a pandemic of a mutable RNA virus was already known to be a foolish, reckless and dangerous strategy.

These experimental genetic vaccines are unsafe, do not confer cross-protective immunity and will devastate our society's health, according to the academic literature and data we already have available.

We urgently need immediate public debate. I am absolutely willing to present all of this evidence personally to your organisation, in any capacity, under any reasonable set of conditions. The public deserves to be immediately informed of all the risks that we already know. Failure to immediately inform parents of all the risks their children would be exposed to is immoral, disgraceful and completely unacceptable. I do not believe our society would ever heal from such a betrayal by its leaders in politics and public health.

If you disagree that the public deserve to be immediately informed of all the risks, please justify your rationale.

Yours sincerely,

Jonathan Weissman

Jonathan Weissman BSc MSc MSc

On Saturday 27 November 2021, at the Emergency Health and Truth Summit in Northern Ireland, I issued a call for an IMMEDIATE MORATORIUM on the experimental COVID-19 genetic vaccines currently deployed in the UK, especially for children. In my talk, I define a risk-benefit framework in 4 key areas:

1. Safety – Are the vaccines safe for human consumption?

2. Efficacy – Do the vaccines protect against infection, transmission, severe disease and death?

3. Strategic Viability – Will the vaccines provide beneficial immunological memory for the medium and long term and is their universal deployment wise?

4. Ethics – Have the vaccines been developed, manufactured, tested and marketed ethically?

According to this framework, I judge that the risk from all the experimental COVID-19 genetic vaccines deployed in the UK far outweighs the benefit and conclude that we therefore require an IMMEDIATE MORATORIUM.

1. COVID-19 Vaccines Yellow Card Analysis. UK Freedom Project. Accessed November 27, 2021.
https://ukfreedomproject.org/covid-19-vaccines-yellow-card-analysis/

2. Summary of the Public Assessment Report for COVID-19 Vaccine Pfizer/BioNTech. MHRA. Accessed November 27, 2021. https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccine

3. Maugeri M, Nawaz M, Papadimitriou A, et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat. Commun. 2019;10(1). doi:10.1038/s41467-019-12275-6

4. Cui S, Wang Y, Gong Y, et al. Correlation of the cytotoxic effects of cationic lipids with their headgroups. Toxicol. Res. 2018;7(3):473-479. doi:10.1039/c8tx00005k

5. Ehlinger C, Spear N, Doddareddy R, Shankar G, Schantz A. A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum. J. Immunol. Methods. 2019;474. doi:10.1016/j.jim.2019.112669

6. Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. JCR. 2015;217:345-351. doi:10.1016/j.jconrel.2015.08.007 

7. SARS-CoV-2 MRNA Vaccine (BNT162, PF-07302048) 2.6.4 薬物動態試験の概要文. Pfizer Inc. Accessed August 29, 2021. https://www.pmda.go.jp/drugs/2021/P20210212001/672212000_30300AMX00231_I100_1.pdf

8. Ogata AF, Cheng C-A, Desjardins M, et al. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clin. Infect. Dis. Published online May 20, 2021. doi:10.1093/cid/ciab465 

9. Bansal S, Perincheri S, Fleming T, et al. Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines. J Immunol. 2021;207(10):2405-2410. doi:10.4049/jimmunol.2100637

10. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ. Res. Published online 2021:1323-1326. doi:10.1161/CIRCRESAHA.121.318902

11. Raghavan S, Kenchappa DB, Leo MD. SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity. Front. Cardiovasc. Med. 2021;8. doi:10.3389/fcvm.2021.687783 

12. Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 2020;13(1). doi:10.1186/s13045-020-00954-7

13. Zhang L, Zhou L, Bao L, et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct. Target. Ther. 2021;6(1):337. doi:10.1038/s41392-021-00719-9

14. Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl. Acad. Sci. U.S.A.. 2006;103(47):17985-17990. doi:10.1073/pnas.0605545103 

15. Young CN, Davisson RL. Angiotensin-II, the brain, and hypertension: An update. Hypertension. 2015;66(5):920-926. doi:10.1161/HYPERTENSIONAHA.115.03624 57. 

16. Suzuki YJ, Gychka SG.SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. Vaccines. 2021;9(1):1-8. doi:10.3390/vaccines9010036

17. Silvagno F, Vernone A, Pescarmona GP. The role of glutathione in protecting against the severe inflammatory response triggered by covid-19. Antioxidants. 2020;9(7):1-16. doi:10.3390/antiox9070624 

18. Singh N, Bharara Singh A. S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study. Transl. Oncol. 2020;13(10):100814. doi:10.1016/j.tranon.2020.100814

19. Jiang H, Mei YF. SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro. Viruses. 2021;13(10):2056. Published 2021 Oct 13. doi:10.3390/v13102056

20. Konstantin Föhse F, Geckin B, Overheul GJ, et al. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses. medRxiv: the preprint server for health sciences. Published online May 6, 2021. doi:10.1101/2021.05.03.21256520

21. COVID-19 vaccine surveillance report: Week 42. UK Health Security Agency. Accessed November 27, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027511/Vaccine-surveillance-report-week-42.pdf

22. Smits VAJ, Hernández-Carralero E, Paz-Cabrera MC, et al. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Biochem. Biophys. Res. Commun. 2021;543:45-49. doi:10.1016/j.bbrc.2021.01.073

23. le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457-462. doi:10.1038/s41586-020-2550-z

24. van Vinh Chau N, My Ngoc N, Anh Nguyet L, et al. An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine. 2021;41(101143). doi:10.1016/j.eclinm.2021.101143

25. Area FB, Servellita CV, Morris M-K, et al. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. medRxiv: the preprint server for health sciences. Published online August 25, 2021. doi:10.1101/2021.08.19.21262139

26. Arora, P, Rocha, C, Kempf, A, et al. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. Cell. Mol. Immunol. 2021.18:2673-2675. doi:10.1038/s41423-021-00779-5

27. Martin DP, Weaver S, Tegally H, et al. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape. medRxiv: the preprint server for health sciences. Published online March 5, 2021. doi:10.1101/2021.02.23.21252268

28. Long term evolution of SARS-CoV-2, 26 July 2021. Scientific Advisory Group for Emergencies. Accessed November 27, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1007566/S1335_Long_term_evolution_of_SARS-CoV-2.pdf

29. Brown EL, Essigmann HT, Anderson M, et al. Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19 HCoV-NL63 and HCoV-HKU1). E. ASM. 2021;6(2):1-6. doi:10.1128/mSphere.00056-21

30. Francis, T. On the Doctrine of Original Antigenic Sin. Proc. Am. Philos. Soc. 1960;104(6):572-78. https://www.jstor.org/stable/985534

31. Vaccines and Related Biological Products Advisory Committee Meeting, Wednesday, May 16, 2001. FDA Center for Biologics Evaluation and Research. Accessed November 27, 2021.
https://wayback.archive-it.org/7993/20170404095417/https:/www.fda.gov/ohrms/dockets/ac/01/transcripts/3750t1_01.pdf

32. Guidance on Getting the COVID-19 Vaccine. Children of God For Life. Accessed November 27, 2021.
https://cogforlife.org/guidance/

33. PER C6 & HEK-293. Children of God For Life. Accessed November 27, 2021.
https://cogforlife.org/per-c6-hek-293/

34. Brown RB. Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials. Medicina (Lithuania). 2021;57(3):1-9. doi:10.3390/medicina57030199

35. Vaccines and Related Biological Products Advisory Committee Meeting, December 10, 2020: FDA Briefing Document, Pfizer-BioNTech COVID-19 Vaccine. FDA. Accessed November 27, 2021.
https://www.fda.gov/media/144245/

36. BMJ Investigation. Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial. BMJ. 2021:375:1-3. doi:10.1136/bmj.n2635

37. Naik, R (Review Committee Chair, DVRPA/OVRR). Summary Basis for Regulatory Action (COMIRNATY). FDA. Accessed November 27, 2021. https://www.fda.gov/media/151733/download

38. BioNTech SE. Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents. Pfizer Inc. Published March 31, 2021. Accessed September 6, 2021.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal

39. Frenck RW, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N. Engl. J. Med. 2021;385(3):239-250. doi:10.1056/nejmoa2107456

40. #SilencedVoices: Vaccine-damaged Americans Tearfully Describe SEVERE Side Effects After Taking Covid Vaccine On Sen. Ron Johnson’s ‘Give an Ear’ Panel. NewsRescue. Published June 30, 2021. Accessed September 6, 2021.
https://newsrescue.com/silencedvoices-vaccine-damaged-americans-tearfully-describe-severe-side-effects-after-taking-covid-vaccine-on-sen-ron-j ohnsons-give-an-ear-panel/

41. BNT162b2, 3.2.P.1: Description and Composition of the Drug Product. Pfizer. Accessed November 27, 2021. https://www.whatdotheyknow.com/request/801347/response/1912708/attach/3/description%20and%20composition%20redacted.pdf

42. Exact quantity of Water for Injection pre and post dilution in BTN162b2. WhatDoTheyKnow. Accessed November 27, 2021. https://www.whatdotheyknow.com/request/exact_quantity_of_water_for_inje?unfold=1#incoming-1920922

43. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA. 2020;323(23):2427–2429. doi:10.1001/jama.2020.8707

44. Loske J, Röhmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat. Biotechnol. Published online 2021. doi:10.1038/s41587-021-01037-9

45. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006;127(3):274-281. doi:10.1016/j.mad.2005.11.001